



DOCKET NO.: C1039.70074US00

Ifw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Krieg et al.
Serial No.: 10/679,710
Confirmation No.: 9983
Filed: October 3, 2003
For: IMMUNOSTIMULATORY NUCLEIC ACID MOLECULES
Examiner: Michelle S. Horning
Art Unit: 1648

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 31st day of January, 2007.


Emily E. Ziauskas

MAIL STOP AMENDMENT

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449 with cited references
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:


Helen C. Lockhart, Ph.D., Reg. No.: 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: C1039.70074US00

Date: January 31, 2007

xNDDx



DOCKET NO.: C1039.70074US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Krieg et al.
Serial No.: 10/679,710
Confirmation No.: 9983
Filed: October 3, 2003
For: IMMUNOSTIMULATORY NUCLEIC ACID
MOLECULES
Examiner: Michelle S. Horning
Art Unit: 1648

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 31st day of January, 2007.

Emily E. Zukauskas
Emily E. Zukauskas

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Docket No.</u>
09/316,199	05-21-1999	McCluskie et al.	*C1040.70006US00
09/337,584	06-21-1999	Krieg et al.	*C1039.70020US00
09/337,893	06-21-1999	Krieg	*C1039.70022US00
09/630,319	07-31-2000	Krieg et al.	*C1039.70042US00
09/669,187	09-25-2000	Krieg et al.	*C1039.70035US00
09/786,436	09-03-1999	Wagner et al.	C1041.70010US00
10/187,489	07-02-2002	Krieg et al.	C1039.70062US00
10/811,226	03-26-2004	Wagner et al.	*C1041.70005US01
11/503,377	08-11-2006	Krieg et al.	*C1039.70061US01
11/507,079	08-18-2006	Krieg et al.	*C1039.70035US04
11/526,197	09-22-2006	Krieg et al.	*C1039.70048US23
11/526,896	09-22-2006	Bratzler et al.	*C1037.70013US03
11/542,845	10-04-2006	Krieg et al.	*C1037.70048US01
11/543,314	10-04-2006	Lipford et al.	*C1041.70036US02
11/595,823	11-10-2006	Wagner et al.	*C1041.70035US01
11/598,207	11-10-2006	Krieg et al.	*C1039.70048US24
11/603,978	11-22-2006	Forsbach et al.	*C1041.70053US02
11/629,106	12-08-2006	Lipford et al.	*C1041.70027US01
11/645,106	12-22-2006	Krieg et al.	*C1039.70083US17

*A copy of this reference is not provided as the Office has waived the requirement under 37 C.F.R. 1.98(a)(2)(iii) for submitting a copy of a cited U.S. patent application if it is scanned to the Image File Wrapper system and is available on Private PAIR.

PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following are remarks concerning the other information cited:

The instant patent application derives priority from US 6,207,646 B1, which was involved in an Interference (Interference No. 105,171). In view of the priority, Applicants have included on the attached 1449 a listing of all of the motions filed, the judgment rendered by the Board of Patent Appeals and Interferences, appeal briefs, and appeal decision, which considered the 35 U.S.C. §135(b)(1) motion dispositive. Copies of these documents were previously submitted in Serial No. 09/818,918, filed March 27, 2001, to which the instant application derives priority. If the Examiner would like any additional information on this subject, she is encouraged to contact Applicant's representative at the number listed below.

PART IV: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

Serial No.: 10/679,710
Conf. No.: 9983

- 4 -

Art Unit: 1648

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By:


Helen C. Lockhart, Ph.D., Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: C1039.70074US00

Date: January 31, 2007

xNDDx

APPLICATION NO.: 10/679,710

ATTY. DOCKET NO.: C1039.70074US00

FILING DATE: October 3, 2003

CONFIRMATION NO.: 9983

APPLICANT: Krieg et al.

GROUP ART UNIT: 1648

EXAMINER: Michelle S. Horning

FEB 02 2007
PATENT & TRADEMARK OFFICE

Sheet 1 of 17

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1	5,594,122		Friesen	01-14-1997
	A2	5,663,153		Hutcherson et al.	09-02-1997
	A3	5,679,647		Carson et al.	10-21-1997
	A4	5,723,335		Hutcherson et al.	03-03-1998
	A5	5,728,518		Carmichael	03-17-1998
	A6	5,804,566		Carson et al.	09-08-1998
	A7	5,849,719		Carson et al.	12-15-1998
	A8	5,955,059		Gilchrest et al.	09-21-1999
	A9	6,086,898		DeKruyff et al.	07-11-2000
	A10	6,174,872	B1	Carson et al.	01-16-2001
	A11	6,194,388	B1	Krieg et al.	02-27-2001
	A12	6,207,646	B1	Krieg et al.	03-27-2001
	A13	6,214,806	B1	Krieg et al	04-10-2001
	A14	6,218,371	B1	Krieg et al.	04-17-2001
	A15	6,221,882		Macfarlane	04-24-2001
	A16	6,225,292	B1	Raz et al.	05-01-2001
	A17	6,239,116	B1	Krieg et al.	05-29-2001
	A18	6,339,068	B1	Krieg et al.	01-15-2002
	A19	6,339,630		Macfarlane	06-04-2002
	A20	6,406,705	B1	Davis et al.	06-18-2002
	A21	6,426,336	B1	Carson et al.	07-30-2002
	A22	6,429,199	B1	Krieg et al.	08-06-2002
	A23	6,479,504		Macfarlane et al.	11-12-2002
	A24	6,498,148	B1	Raz	12-24-2002
	A25	6,514,948	B1	Raz et al.	02-04-2003
	A26	6,521,637		Macfarlane	02-18-2003
	A27	6,534,062	B1	Raz et al.	03-18-2003
	A28	6,552,006	B2	Raz et al.	04-22-2003
	A29	6,558,670	B1	Friede et al.	05-06-2003
	A30	6,562,798	B1	Schwartz	05-13-2003
	A31	6,589,940	B1	Raz et al.	07-08-2003
	A32	6,610,308		Haensler	08-26-2003
	A33	6,610,661	B1	Carson et al.	08-26-2003

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet 2 of 17

APPLICATION NO.:	10/679,710	ATTY. DOCKET NO.:	C1039.70074US00
FILING DATE:	October 3, 2003	CONFIRMATION NO.:	9983
APPLICANT:	Krieg et al.		
GROUP ART UNIT:	1648	EXAMINER:	Michelle S. Horning

A34	6,613,751	B1	Raz et al.	09-02-2003
A35	6,653,292	B1	Krieg et al.	11-25-2003
A36	6,727,230	B1	Hutcherson et al.	04-27-2004
A37	6,737,066	B1	Moss	05-18-2004
A38	6,821,957	B1	Krieg et al.	11-23-2004
A39	6,835,395	B1	Semple et al.	12-28-2004
A40	6,893,821	B2	Raz et al.	05-17-2005
A41	6,943,240		Bauer et al.	09-13-2005
A42	6,949,520		Hartmann et al.	09-27-2005
A43	6,951,845		Carson et al.	10-04-2005
A44	7,001,890		Wagner et al.	02-26-2006
A45	2001-0046967	A1	Van Nest et al.	11-29-2001
A46	2002-0028784	A1	Van Nest et al.	03-07-2002
A47	2002-0042387	A1	Raz et al.	04-11-2002
A48	2002-0055477	A1	Van Nest et al.	05-09-2002
A49	2002-0086839	A1	Raz et al.	07-04-2002
A50	2002-0091097	A1	Bratzler et al.	07-11-2002
A51	2002-0098199	A1	Van Nest et al.	07-25-2002
A52	2002-0107212	A1	Van Nest et al.	08-08-2002
A53	2002-0142977	A1	Raz et al.	10-03-2002
A54	2002-0142978	A1	Raz et al.	10-03-2002
A55	2002-0164341	A1	Davis et al.	11-07-2002
A56	2002-0192184	A1	Carpentier et al.	12-19-2002
A57	2003-0022852	A1	Van Nest et al.	01-30-2003
A58	2003-0026801	A1	Weiner et al.	02-06-2003
A59	2003-0027782	A1	Carson et al.	02-06-2003
A60	2003-0049266	A1	Fearon et al.	03-13-2003
A61	2003-0050261	A1	Krieg et al.	03-13-2003
A62	2003-0050268	A1	Krieg et al.	03-13-2003
A63	2003-0059773	A1	Van Nest et al.	03-27-2003
A64	2003-0064064	A1	Dina et al.	04-03-2003
A65	2003-0078223	A1	Raz et al.	04-24-2003
A66	2003-0091599	A1	Davis et al.	05-15-2003
A67	2003-0092663	A1	Raz et al.	05-15-2003
A68	2003-0100527	A1	Krieg et al.	05-29-2003
A69	2003-0109469	A1	Carson et al.	06-12-2003

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)			APPLICATION NO.: 10/679,710	ATTY. DOCKET NO.: C1039.70074US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: October 3, 2003	CONFIRMATION NO.: 9983
			APPLICANT: Krieg et al.	
Sheet	3	of	17	GROUP ART UNIT: 1648 EXAMINER: Michelle S. Horning

A70	2003-0119773	A1	Raz et al.	06-26-2003
A71	2003-0125284	A1	Raz et al.	07-03-2003
A72	2003-0129251	A1	Van Nest et al.	07-10-2003
A73	2003-0130217	A1	Raz et al.	07-10-2003
A74	2003-0133988	A1	Fearon et al.	07-17-2003
A75	2003-0139364	A1	Krieg et al.	07-24-2003
A76	2003-0143213	A1	Raz et al.	07-31-2003
A77	2003-0148316	A1	Lipford et al.	08-07-2003
A78	2003-0147870	A1	Raz et al.	08-07-2003
A79	2003-0148976	A1	Krieg et al.	08-07-2003
A80	2003-0175731	A1	Fearon et al.	09-18-2003
A81	2003-0176373	A1	Raz et al.	09-18-2003
A82	2003-0176389	A1	Raz et al.	09-18-2003
A83	2003-0181406	A1	Schetter et al.	09-25-2003
A84	2003-0186921	A1	Carson et al.	10-02-2003
A85	2003-0191079	A1	Krieg et al.	10-09-2003
A86	2003-0203861	A1	Carson et al.	10-30-2003
A87	2003-0212026	A1	Krieg et al.	11-13-2003
A88	2003-0212028	A1	Raz et al.	11-13-2003
A89	2003-0216340	A1	Van Nest et al.	11-20-2003
A90	2003-0224010	A1	Davis et al.	12-04-2003
A91	2003-0225016	A1	Fearon et al.	12-04-2003
A92	2003-0232074	A1	Lipford et al.	12-18-2003
A93	2003-0232780	A1	Carson et al.	12-18-2003
A94	2003-0232856	A1	Macfarlane	12-18-2003
A95	2004-0006010	A1	Carson et al.	01-08-2004
A96	2004-0006034	A1	Raz et al.	01-08-2004
A97	2004-0009942	A1	Van Nest et al.	01-15-2004
A98	2004-0009949	A1	Krieg	01-15-2004
A99	2004-0030118	A1	Wagner et al.	02-12-2004
A100	2004-0038922	A1	Haensler et al.	02-26-2004
A101	2004-0053880	A1	Krieg	03-18-2004
A102	2004-0067902	A9	Bratzler et al.	04-08-2004
A103	2004-0067905	A1	Krieg	04-08-2004
A104	2004-0087534	A1	Krieg et al.	05-06-2004
A105	2004-0087538	A1	Krieg et al.	05-06-2004

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)			APPLICATION NO.: 10/679,710	ATTY. DOCKET NO.: C1039.70074US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: October 3, 2003	CONFIRMATION NO.: 9983
			APPLICANT: Krieg et al.	
Sheet	4	of	17	GROUP ART UNIT: 1648 EXAMINER: Michelle S. Horning

A106	2004-0092468	A1	Schwartz et al.	05-13-2004
A107	2004-0092472	A1	Krieg	05-13-2004
A108	2004-0105872	A1	Klinman et al.	06-03-2004
A109	2004-0106568	A1	Krieg et al.	06-03-2004
A110	2004-0131628	A1	Bratzler et al.	07-08-2004
A111	2004-0132677	A1	Fearon et al.	07-08-2004
A112	2004-0132685	A1	Krieg et al.	07-08-2004
A113	2004-0136948	A1	Fearon et al.	07-15-2004
A114	2004-0142469	A1	Krieg et al.	07-22-2004
A115	2004-0143112	A1	Krieg et al.	07-22-2004
A116	2004-0147468	A1	Krieg et al.	07-29-2004
A117	2004-0152649	A1	Krieg	08-05-2004
A118	2004-0152656	A1	Krieg et al.	08-05-2004
A119	2004-0152657	A1	Krieg et al.	08-05-2004
A120	2004-0162258	A1	Krieg et al.	08-19-2004
A121	2004-0162262	A1	Krieg et al.	08-19-2004
A122	2004-0167089	A1	Krieg et al.	08-26-2004
A123	2004-0171150	A1	Krieg et al.	09-02-2004
A124	2004-0171571	A1	Krieg et al.	09-02-2004
A125	2004-0181045	A1	Krieg et al.	09-16-2004
A126	2004-0198680	A1	Krieg	10-07-2004
A127	2004-0198688	A1	Krieg et al.	10-07-2004
A128	2004-0229835	A1	Krieg et al.	11-18-2004
A129	2004-0234512	A1	Wagner et al.	11-25-2004
A130	2004-0235770	A1	Davis et al.	11-25-2004
A131	2004-0235774	A1	Bratzler et al.	11-25-2004
A132	2004-0235777	A1	Wagner et al.	11-25-2004
A133	2004-0235778	A1	Wagner et al.	11-25-2004
A134	2004-0247662	A1	Dow et al.	12-09-2004
A135	2004-0248837	A1	Raz et al.	12-09-2004
A136	2004-0266719	A1	McCluskie et al.	12-30-2004
A137	2005-0004061	A1	Krieg et al.	01-06-2005
A138	2005-0004062	A1	Krieg et al.	01-06-2005
A139	2005-0004144	A1	Carson et al.	01-06-2005
A140	2005-0009774	A1	Krieg et al.	01-13-2005
A141	2005-0013812	A1	Dow et al.	01-20-2005

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICATION NO.: 10/679,710	ATTY. DOCKET NO.: C1039.70074US00
			FILING DATE: October 3, 2003	CONFIRMATION NO.: 9983
			APPLICANT: Krieg et al.	
			GROUP ART UNIT: 1648	EXAMINER: Michelle S. Horning
Sheet	5	of	17	

A142	2005-0031638	A1	Dalemans et al.	02-10-2005
A143	2005-0032734	A1	Davis et al.	02-10-2005
A144	2005-0032736	A1	Krieg et al.	02-10-2005
A145	2005-0037403	A1	Krieg et al.	02-17-2005
A146	2005-0037985	A1	Krieg et al.	02-17-2005
A147	2005-0043529	A1	Davis et al.	02-24-2005
A148	2005-0049215	A1	Krieg et al.	03-03-2005
A149	2005-0049216	A1	Krieg et al.	03-03-2005
A150	2005-0054601	A1	Wagner et al.	03-10-2005
A151	2005-0054602	A1	Krieg et al.	03-10-2005
A152	2005-0059619	A1	Krieg et al.	03-17-2005
A153	2005-0059625	A1	Krieg et al.	03-17-2005
A154	2005-0059626	A1	Van Nest et al.	03-17-2005
A155	2005-0064401	A1	Olek et al.	03-24-2005
A156	2005-0070491	A1	Krieg et al.	03-31-2005
A157	2005-0075302	A1	Hutcherson et al.	04-07-2005
A158	2005-0079152	A1	Bot et al.	04-14-2005
A159	2005-0100983	A1	Bauer et al.	05-12-2005
A160	2005-0101554	A1	Krieg et al.	05-12-2005
A161	2005-0101557	A1	Krieg et al.	05-12-2005
A162	2005-0119273	A1	Lipford et al.	06-02-2005
A163	2005-0123523	A1	Krieg et al.	06-09-2005
A164	2005-0130911	A1	Uhlmann et al.	06-16-2005
A165	2005-0148537	A1	Krieg et al.	07-07-2005
A166	2005-0169888	A1	Hartman et al.	08-04-2005
A167	2005-0171047	A1	Krieg et al.	08-04-2005
A168	2005-0181422	A1	Bauer et al.	08-18-2005
A169	2005-0182017	A1	Krieg	08-18-2005
A170	2005-0197314	A1	Krieg et al.	09-08-2005
A171	2005-0215500	A1	Krieg et al.	09-29-2005
A172	2005-0215501	A1	Lipford et al.	09-29-2005
A173	2005-0233995	A1	Krieg et al.	10-20-2005
A174	2005-0233999	A1	Krieg et al.	10-20-2005
A175	2005-0239732	A1	Krieg et al.	10-27-2005
A176	2005-0239733	A1	Jurk et al.	10-27-2005
A177	2005-0239734	A1	Uhlmann et al.	10-27-2005

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/679,710	ATTY. DOCKET NO.: C1039.70074US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: October 3, 2003	CONFIRMATION NO.: 9983
				APPLICANT: Krieg et al.	
Sheet	6	of	17	GROUP ART UNIT: 1648	EXAMINER: Michelle S. Horning

A178	2005-0239736	A1	Krieg et al.	10-27-2005
A179	2005-0244379	A1	Krieg et al.	11-03-2005
A180	2005-0250726	A1	Krieg et al.	11-10-2005
A181	2005-0256073	A1	Lipford et al.	11-17-2005
A182	2005-0267057	A1	Krieg	12-01-2005
A183	2005-0267064	A1	Krieg et al.	12-01-2005
A184	2005-0277604	A1	Krieg et al.	12-15-2005
A185	2005-0277609	A1	Krieg et al.	12-15-2005
A186	2006-0003955	A1	Krieg et al.	01-05-2006
A187	2006-0003962	A1	Ahluwalia et al.	01-05-2006
A188	2006-0019916	A1	Krieg et al.	01-26-2006
A189	2006-0019923	A1	Davis et al.	01-26-2006
A190	2006-0058251	A1	Krieg et al.	03-16-2006
A191	2006-0089326	A1	Krieg et al.	04-27-2006
A192	2006-0094683	A1	Krieg et al.	05-04-2006
A193	2006-0140875	A1	Krieg et al.	06-29-2006
A194	2006-0154890	A1	Bratzler et al.	07-13-2006
A195	2006-0172966	A1	Lipford et al.	08-03-2006
A196	2006-0188913	A1	Krieg et al.	08-24-2006
A197	2006-0211639	A1	Bratzler et al.	09-21-2006
A198	2006-0211644	A1	Krieg et al.	09-21-2006
A199	2006-0229271	A1	Krieg et al.	10-12-2006
A200	2006-0241076	A1	Uhlmann et al.	10-26-2006
A201	2006-0246035	A1	Ahluwalia et al.	11-02-2006
A202	2006-0286070	A1	Hartmann et al.	12-21-2006
A203	2006-0287263	A1	Davis et al.	12-21-2006
A204	2007-0009482	A1	Krieg et al.	01-11-2007
A205	2007-0010470	A1	Krieg et al.	01-11-2007

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B1	EP	0 302 758	A1	New England Medical Center Hospitals, Inc.	02-08-1989	
	B2	EP	0 468 520	A2	Mitsui Toatsu Chemicals, Inc.	01-29-1992	
	B3	WO	91/12811	A1	ISIS Pharmaceuticals Inc.	09-05-1991	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Sheet

7

of

17

B4	WO	92/03456		ISIS Pharmaceuticals Inc.	03-05-1992	
B5	WO	94/19945	A1	ISIS Pharmaceuticals Inc.	09-15-1994	
B6	WO	97/28259	A1	The Regents of the University of California	08-07-1997	
B7	WO	98/16247	A1	The Regents of the University of California	04-23-1998	
B8	WO	98/49288	A1	Hybridon Inc.	11-05-1998	
B9	WO	98/55495	A2	Dynavax Technologies Corporation	12-10-1998	
B10	WO	99/33488	A2	SmithKline Beecham Biologicals S.A.	07-08-1999	
B11	WO	99/52549	A1	SmithKline Beecham Biologicals S.A.	10-29-1999	
B12	WO	99/62923	A2	Dynavax Technologies Corporation	12-09-1999	
B13	WO	00/20039	A1	The Regents of the University of California	04-13-2000	
B14	WO	00/21556	A1	Dynavax Technologies Corporation	04-20-2000	
B15	WO	00/62787	A1	Regents of the University of California	10-26-2000	
B16	WO	01/12223	A2	Dynavax Technologies Corporation	02-22-2001	
B17	WO	01/35991	A2	Dynavax Technologies Corporation	05-25-2001	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	ABED et al., Interferon-gamma regulation of B lymphocyte differentiation: activation of B cells is a prerequisite for IFN-gamma-mediated inhibition of B cell differentiation. Cell Immunol. 1994 Feb;153(2):356-66.	
	C2	AGRAWAL et al., Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med. 2002 Mar;8(3):114-21.	
	C3	AGRAWAL et al., Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595-9.	
	C4	AGRAWAL et al., Chapter 19: Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals. 1998: 525-43.	
	C5	ANITESCU et al., Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. J Interferon Cytokine Res. 1997 Dec;17(12):781-8.	
	C6	BALLAS et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol. 1996 Sep 1;157(5):1840-5.	
	C7	BOGGS et al., Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):461-71.	
	C8	BRANDA et al., Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem Pharmacol. 1993 May 25;45(10):2037-43.	
	C9	BRANDA et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J Lab Clin Med. 1996 Sep;128(3):329-38.	

EXAMINER:

DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/679,710	ATTY. DOCKET NO.: C1039.70074US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: October 3, 2003	CONFIRMATION NO.: 9983
				APPLICANT: Krieg et al.	
Sheet	8	of	17	GROUP ART UNIT: 1648	EXAMINER: Michelle S. Horning

C10	BRAZOLOT et al., CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15553-8.	
C11	BRUNNER et al., Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol. 2000 Dec 1;165(11):6278-86.	
C12	CARPENTIER et al., Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res. 2000 Jun;6(6):2469-73.	
C13	CARSON et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med. 1997 Nov 17;186(10):1621-2.	
C14	CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol. 1997 Aug;84(2):185-93.	
C15	CHU et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997 Nov 17;186(10):1623-31.	
C16	COSSUM et al., Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther. 1993 Dec;267(3):1181-90.	
C17	COWDERY et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol. 1996 Jun 15;156(12):4570-5.	
C18	COWSERT et al., In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrob Agents Chemother. 1993 Feb;37(2):171-7.	
C19	DEMEL et al., Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins. Clin Chem Lab Med. 1999 Mar;37(3):199-204.	
C20	FRANCOIS et al., Examination of the inhibitory and stimulatory effects of IFN-alpha, -beta, and -gamma on human B-cell proliferation induced by various B-cell mitogens. Clin Immunol Immunopathol. 1988 Sep;48(3):297-306.	
C21	FULTZ et al., Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation. AIDS Res Hum Retroviruses. 1992 Feb;8(2):313-7.	
C22	GALLICHAN et al., Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine. 1995 Nov;13(16):1589-95.	
C23	GARBI et al., CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol. 2004 May 15;172(10):5861-9.	
C24	HAFNER et al., Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res. 2001 Jul 15;61(14):5523-8.	
C25	HALPERN et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol. 1996 Jan 10;167(1):72-8.	
C26	HASLETT et al., Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. J Infect Dis. 2000 Apr;181(4):1264-72. Epub 2000 Apr 05.	
C27	HAVLIR et al., Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med. 1998 Oct 29;339(18):1261-8.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/679,710	ATTY. DOCKET NO.: C1039.70074US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: October 3, 2003	CONFIRMATION NO.: 9983
				APPLICANT: Krieg et al.	
Sheet	9	of	17	GROUP ART UNIT: 1648	EXAMINER: Michelle S. Horning

C28	HINKULA et al., Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. <i>J Virol.</i> 1997 Jul;71(7):5528-39.	
C29	IVERSEN et al., Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. <i>Antisense Res Dev.</i> 1994 Spring;4(1):43-52.	
C30	JAKOB et al., Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. <i>J Immunol.</i> 1998 Sep 15;161(6):3042-9.	
C31	JIANG et al., Enhancing immunogenicity by CpG DNA. <i>Curr Opin Mol Ther.</i> 2003 Apr;5(2):180-5.	
C32	JOHNSON et al., Non-specific resistance against microbial infections induced by polyribonucleotide complexes. In: <i>Immunopharmacology of infection diseases: Vaccine adjuvants and modulators of non-specific resistance.</i> 1987: 291-301.	
C33	KATAOKA et al., Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG. <i>Jpn J Cancer Res.</i> 1992 Mar;83(3):244-7.	
C34	KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from <i>Mycobacterium bovis</i> BCG complexed with poly-L-lysine and carboxymethylcellulose. <i>Jpn J Med Sci Biol.</i> 1990 Oct;43(5):171-82.	
C35	KIMURA et al., Binding of oligoguanosine to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. <i>J Biochem (Tokyo).</i> 1994 Nov;116(5):991-4.	
C36	KLINMAN et al., Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. <i>Drug News Perspect.</i> 2000 Jun;13(5):289-96.	
C37	KLINMAN et al., Immunotherapeutic uses of CpG oligodeoxynucleotides. <i>Nat Rev Immunol.</i> 2004 Apr;4(4):249-58.	
C38	KLINMAN et al., Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. <i>Springer Semin Immunopathol.</i> 2000;22(1-2):173-83.	
C39	KLINMAN et al., Immune recognition of foreign DNA: a cure for bioterrorism? <i>Immunity.</i> 1999 Aug;11(2):123-9.	
C40	KLINMAN et al., Contribution of CpG motifs to the immunogenicity of DNA vaccines. <i>J Immunol.</i> 1997 Apr 15;158(8):3635-9.	
C41	KLINMAN et al., CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. <i>Proc Natl Acad Sci U S A.</i> 1996 Apr 2;93(7):2879-83.	
C42	KRIEG et al., Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs. <i>American College of Rheumatology 58th National Scientific Meeting.</i> Minneapolis, Minnesota, October 22, 1994. <i>Abstracts. Arthritis Rheum.</i> 1994 Sep;37(9 Suppl).	
C43	KRIEG et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. <i>Antisense Nucleic Acid Drug Dev.</i> 1996 Summer;6(2):133-9.	
C44	KRIEG et al., Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? <i>Antisense Res Dev.</i> 1995 Winter;5(4):241.	
C45	KRIEG et al., Leukocyte stimulation by oligodeoxynucleotides, <i>Applied Antisense Oligonucleotide Technology,</i> 1998; 431-448.	
C46	KRIEG, CpG DNA: a pathogenic factor in systemic lupus erythematosus? <i>J Clin Immunol.</i> 1995 Nov;15(6):284-92.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/679,710	ATTY. DOCKET NO.: C1039.70074US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: October 3, 2003	CONFIRMATION NO.: 9983
				APPLICANT: Krieg et al.	
Sheet	10	of	17	GROUP ART UNIT: 1648	EXAMINER: Michelle S. Horning

C47	KRIEG et al., CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 6;374(6522):546-9.	
C48	KRIEG et al., Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholestrylo moiety increases cellular association and improves efficacy. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1048-52.	
C49	KRIEG et al., The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 1998 Jan;6(1):23-7.	
C50	KRIEG, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med. 1996 Aug;128(2):128-33.	
C51	KRIEG et al., Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med. 1999 Jan-Feb;1(1):56-63.	
C52	KRIEG et al., Applications of immune stimulatory CpG DNA for antigen-specific and antigen-nonspecific cancer immunotherapy. Eur J Canc. 1999 Oct; 35/Suppl4:S10. Abstract #14.	
C53	KRIEG et al., Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today. 2000 Oct;21(10):521-6.	
C54	KRIEG et al., Chapter 8: Immune Stimulation by Oligonucleotides. in Antisense Research and Application. Crooke, editor. 1998; 243-62.	
C55	KRIEG et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation. J Immunol. 1989 Oct 15;143(8):2448-51.	
C56	KRIEG et al., Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal L. monocytogenes challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996: 116.	
C57	KRIEG et al., Chapter 17:Immune stimulation by oligonucleotides. in Antisense Drug Tech. 2001;1394:471-515.	
C58	KRIEG et al., Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999 Dec 10;1489(1):107-16.	
C59	KRIEG et al., The CpG motif: Implications for clinical immunology. BioDrugs. 1998 Nov 1;10(5):341-6.	
C60	KRIEG, The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000 Feb;12(1):35-43.	
C61	KRIEG et al., Mechanism of action of CpG DNA. Curr Top Microbiol Immunol. 2000;247:1-21.	
C62	KRIEG et al., Mechanisms and therapeutic applications of immune stimulatory CpG DNA. Pharmacol Ther. 1999 Nov;84(2):113-20.	
C63	KRIEG et al., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12631-6.	
C64	KRIEG et al., CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol. 1998 Sep 1;161(5):2428-34.	
C65	KRIEG et al., CpG DNA: a novel immunomodulator. Trends Microbiol. 1999 Feb;7(2):64-5.	
C66	KRIEG, Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol. 2000;22(1-2):97-105.	
C67	KRIEG et al., Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge. Vaccines. 1997; 97:77-9.	
C68	KRIEG et al., Infection. In McGraw Hill Book. 1996: 242-3.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/679,710	ATTY. DOCKET NO.: C1039.70074US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: October 3, 2003	CONFIRMATION NO.: 9983
				APPLICANT: Krieg et al.	
Sheet	11	of	17	GROUP ART UNIT: 1648	EXAMINER: Michelle S. Horning

C69	KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.	
C70	KUBY et al., Editors, "Chapter 13: Cytokines", Immunology: Second Edition, W.H. Freeman and Company, New York. 1994. p297-322.	
C71	KULKARNI et al., Effect of dietary nucleotides on response to bacterial infections. JPEN J Parenter Enteral Nutr. 1986 Mar-Apr;10(2):169-71.	
C72	KURAMOTO et al., Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol. 1992 Jul;14(5):773-82.	
C73	KURAMOTO et al., Oligonucleotide sequences required for natural killer cell activation. Jpn J Cancer Res. 1992 Nov;83(11):1128-31.	
C74	KURAMOTO et al., In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. Microbiol Immunol. 1989;33(11):929-40.	
C75	LEDERMAN et al., Polydeoxyguanine motifs in a 12-mer phosphorothioate oligodeoxynucleotide augment binding to the v3 loop of HIV-1 gp120 and potency of HIV-1 inhibition independency of G-tetrad formation. Antisense Nucleic Acid Drug Dev. 1996 Winter;6(4):281-9.	
C76	LEIBSON et al., Role of gamma-interferon in antibody-producing responses. Nature. 1984 Jun 28-Jul 4;309(5971):799-801.	
C77	LETSINGER et al., Cholestryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6553-6.	
C78	LETSINGER et al., Synthesis and properties of modified oligonucleotides. Nucleic Acids Symp Ser. 1991;(24):75-8.	
C79	LIPFORD et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol. 1997 Sep;27(9):2340-4.	
C80	LIPFORD et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol. 1997 Dec;27(12):3420-6.	
C81	LIU et al., Recombinant interleukin-6 protects mice against experimental bacterial infection. Infect Immun. 1992 Oct;60(10):4402-6.	
C82	LIU et al., CpG ODN is an effective adjuvant in immunization with tumor antigen. J Invest Med. 1997 Sept;45(7):333A.	
C83	LOTZ et al., Effects of recombinant human interferons on rheumatoid arthritis B lymphocytes activated by Epstein-Barr virus. J Rheumatol. 1987 Feb;14(1):42-5.	
C84	MANCILLA-RAMIREZ et al., [Phosphatidylcholine induces an increase in the production of interleukin-6 and improves survival of rats with neonatal sepsis caused by Klebsiella pneumoniae] Gac Med Mex. 1995 Jan-Feb;131(1):14-22. Spanish. Abstract only.	Yes – Abstract
C85	MARDH et al., Alternaria alternata as a cause of opportunistic fungal infections in man. Scand J Infect Dis Suppl. 1978;(16):36-40.	
C86	MATSUKURA et al., Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4244-8.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/679,710	ATTY. DOCKET NO.: C1039.70074US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: October 3, 2003	CONFIRMATION NO.: 9983
				APPLICANT: Krieg et al.	
Sheet	12	of	17	GROUP ART UNIT: 1648	EXAMINER: Michelle S. Horning

C87	MESSINA et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. <i>Cell Immunol.</i> 1993 Mar;147(1):148-57.	
C88	METZGER et al., Enhancement of humoral immunity by interleukin-12. <i>Ann N Y Acad Sci.</i> 1996 Oct 31;795:100-15.	
C89	MICONNET et al., CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. <i>J Immunol.</i> 2002 Feb 1;168(3):1212-8.	
C90	MOJCIK et al., Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. <i>Clin Immunol Immunopathol.</i> 1993 May;67(2):130-6.	
C91	MOND et al., Recombinant interferon-gamma inhibits the B cell proliferative response stimulated by soluble but not by Sepharose-bound anti-immunoglobulin antibody. <i>J Immunol.</i> 1985 Oct;135(4):2513-7.	
C92	MOSEMAN et al., Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. <i>J Immunol.</i> 2004 Oct 1;173(7):4433-42.	
C93	MOSS et al., In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides. <i>Vaccine.</i> 2000 Jan 6;18(11-12):1081-7.	
C94	PISETSKY et al., Mechanisms of autoantibody production in autoimmune MRL mice. <i>J Exp Med.</i> 1980 Nov 1;152(5):1302-10.	
C95	PISETSKY et al., The immunologic properties of DNA. <i>J Immunol.</i> 1996 Jan 15;156(2):421-3.	
C96	PISETSKY et al., Immunological properties of bacterial DNA. <i>Ann N Y Acad Sci.</i> 1995 Nov 27;772:152-63.	
C97	PISETSKY et al., Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. <i>Life Sci.</i> 1994;54(2):101-7.	
C98	PISETSKY, Immunologic consequences of nucleic acid therapy. <i>Antisense Res Dev.</i> 1995 Fall;5(3):219-25.	
C99	PISETSKY et al., Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. <i>Mol Biol Rep.</i> 1993 Oct;18(3):217-21.	
C100	PISETSKY, The influence of base sequence on the immunostimulatory properties of DNA. <i>Immunol Res.</i> 1999;19(1):35-46.	
C101	RAZ et al., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. <i>Proc Natl Acad Sci U S A.</i> 1996 May 14;93(10):5141-5.	
C102	RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. <i>ACR Poster Session C: Cytokines and Inflammatory Mediators.</i> 1996 Oct 20; Abstract 615.	
C103	REYNOLDS et al., Inhibition of B lymphocyte activation by interferon-gamma. <i>J Immunol.</i> 1987 Aug 1;139(3):767-73.	
C104	ROMAN et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. <i>Nat Med.</i> 1997 Aug;3(8):849-54.	
C105	SATO et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. <i>Science.</i> 1996 Jul 19;273(5273):352-4.	
C106	SATOH et al., Morphological and immunohistochemical characteristics of the heterogeneous prostate-like glands (paraurethral gland) seen in female Brown-Norway rats. <i>Toxicol Pathol.</i> 2001 Mar-Apr;29(2):237-41.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/679,710	ATTY. DOCKET NO.: C1039.70074US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: October 3, 2003	CONFIRMATION NO.: 9983
				APPLICANT: Krieg et al.	
Sheet	13	of	17	GROUP ART UNIT: 1648	EXAMINER: Michelle S. Horning

C107	SCHWARTZ et al., Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. <i>J Immunol.</i> 1999 Jul 1;163(1):224-31.	
C108	SEDEGAH et al., Interleukin 12 induction of interferon gamma-dependent protection against malaria. <i>Proc Natl Acad Sci U S A.</i> 1994 Oct 25;91(22):10700-2.	
C109	SIDMAN et al., Gamma-interferon is one of several direct B cell-maturing lymphokines. <i>Nature.</i> 1984 Jun 28-Jul 4;309(5971):801-4.	
C110	SJOLANDER et al., Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins. <i>Scand J Immunol.</i> 1996 Feb;43(2):164-72.	
C111	SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. <i>J Interferon Cytokine Res.</i> 1996 Oct;16(10):799-803.	
C112	SPARWASSER et al., Bacterial DNA causes septic shock. <i>Nature.</i> 1997 Mar 27;386(6623):336-7.	
C113	SPARWASSER et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. <i>Eur J Immunol.</i> 1997 Jul;27(7):1671-9.	
C114	STEIN et al., Non-antisense effects of oligodeoxynucleotides. <i>Antisense Technology.</i> 1997; ch11: 241-64.	
C115	STEIN et al., Antisense oligonucleotides as therapeutic agents--is the bullet really magical? <i>Science.</i> 1993 Aug 20;261(5124):1004-12.	
C116	STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. <i>Antisense Res Dev.</i> 1994 Summer;4(2):67-9.	
C117	SUN et al. Type I interferon-mediated stimulation of T cells by CpG DNA. <i>J Exp Med.</i> 1998 Dec 21;188(12):2335-42.	
C118	SUN et al. Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons. <i>Springer Semin Immunopathol.</i> 2000;22(1-2):77-84.	
C119	TOKUNAGA et al., A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth. <i>Jpn J Cancer Res.</i> 1988 Jun;79(6):682-6.	
C120	TOKUNAGA et al., Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells. <i>Microbiol Immunol.</i> 1992;36(1):55-66.	
C121	VERTHELYI et al., Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. <i>Clin Immunol.</i> 2003 Oct;109(1):64-71.	
C122	VOLLMER et al., Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. <i>Eur J Immunol.</i> 2004 Jan;34(1):251-62.	
C123	WAAG et al., Injection of inactivated phase I <i>Coxiella burnetii</i> increases non-specific resistance to infection and stimulates lymphokine production in mice. <i>Ann N Y Acad Sci.</i> 1990;590:203-14.	
C124	WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. <i>Proc Natl Acad Sci U S A.</i> 1997 Sep 30;94(20):10833-7.	
C125	WYATT et al. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. <i>Proc Natl Acad Sci U S A.</i> 1994 Feb 15;91(4):1356-60.	

EXAMINER:

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/679,710	ATTY. DOCKET NO.: C1039.70074US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: October 3, 2003	CONFIRMATION NO.: 9983
				APPLICANT: Krieg et al.	
Sheet	14	of	17	GROUP ART UNIT: 1648	EXAMINER: Michelle S. Horning

C126	YAMAMOTO et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. <i>Microbiol Immunol.</i> 1994;38(10):831-6.	
C127	YAMAMOTO et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. <i>J Immunol.</i> 1992 Jun 15;148(12):4072-6.	
C128	YAMAMOTO et al., [Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from <i>Mycobacterium bovis</i> BCG] <i>Kekkaku.</i> 1994 Sep;69(9):571-4. Japanese.	
C129	YAMAMOTO et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. <i>Antisense Res Dev.</i> 1994 Summer;4(2):119-22.	
C130	YAMAMOTO et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. <i>Jpn J Cancer Res.</i> 1994 Aug;85(8):775-9. Abstract Only.	
C131	YI et al., Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. <i>J Immunol.</i> 1996 Dec 15;157(12):5394-402.	
C132	YI et al., IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. <i>J Immunol.</i> 1996 Jan 15;156(2):558-64.	
C133	ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. <i>Antisense Nucleic Acid Drug Dev.</i> 1997 Oct;7(5):495-502.	
*C134	Patent Interference No. 105,171. Iowa Preliminary Motion 3 (for judgment based on failure to comply with 35 U.S.C. 135(b)). (Electronically filed, unsigned). June 7, 2004.	
*C135	Patent Interference No. 105,171. Iowa Preliminary Motion 4 (for judgment of no interference in fact). (Electronically filed, unsigned). June 7, 2004.	
*C136	Patent Interference No. 105,171. Iowa Preliminary Motion 5 (for judgment based on lack of enablement). (Electronically filed, unsigned). June 7, 2004.	
*C137	Patent Interference No. 105,171. Iowa Preliminary Motion 6 (for judgment based on lack of adequate written description). (Electronically filed, unsigned). June 7, 2004.	
*C138	Patent Interference No. 105,171. Iowa Preliminary Motion 7 (motion to redefine interference to designate claims as not corresponding to the Count). (Electronically filed, unsigned). June 7, 2004.	
*C139	Patent Interference No. 105,171. Iowa Preliminary Motion 8 (contingent motion to redefine the Count). (Electronically filed, unsigned). June 7, 2004.	
*C140	Patent Interference No. 105,171. Iowa Preliminary Motion 9 (motion for benefit of earlier application). (Electronically filed, unsigned). June 7, 2004.	
*C141	Patent Interference No. 105,171. Iowa Preliminary Motion 10 (contingent motion to redefine the interference by adding a continuation application). (Electronically filed, unsigned). July 2, 2004.	
*C142	Patent Interference No. 105,171. Regents of the University of California Opposition 3 (to Iowa Preliminary Motion 3 for judgment under 35 USC 135(b)). September 9, 2004.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/679,710	ATTY. DOCKET NO.: C1039.70074US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: October 3, 2003	CONFIRMATION NO.: 9983
				APPLICANT: Krieg et al.	
Sheet	15	of	17	GROUP ART UNIT: 1648	EXAMINER: Michelle S. Horning

*C143	Patent Interference No. 105,171. Regents of the University of California Opposition 4 (to Iowa Preliminary Motion 4 for judgment of no interference in fact). September 9, 2004.	
*C144	Patent Interference No. 105,171. Regents of the University of California Opposition 5 (to Iowa Preliminary Motion 5 for judgment that UC's claim is not enabled). September 9, 2004.	
*C145	Patent Interference No. 105,171. Regents of the University of California Opposition 6 (to Iowa Preliminary Motion 6 for judgment based on lack of adequate written description). September 9, 2004.	
*C146	Patent Interference No. 105,171. Regents of the University of California Opposition 7 (to Iowa Preliminary Motion 7 to redefine the interference). September 9, 2004.	
*C147	Patent Interference No. 105,171. Regents of the University of California Opposition 8 (to Iowa Preliminary Motion 8 to redefine the Count). September 9, 2004.	
*C148	Patent Interference No. 105,171. Regents of the University of California Response 9 (to Iowa Contingent Motion 9 for benefit). September 9, 2004.	
*C149	Patent Interference No. 105,171. Regents of the University of California Opposition 10 (to Iowa Contingent Motion 10 to redefine the interference). September 9, 2004.	
*C150	Patent Interference No. 105,171. Regents of the University of California Opposition 11 (to Iowa Contingent Motion 11 to suppress). October 15, 2004.	
*C151	Patent Interference No. 105,171. Iowa Reply 3 (in support of Iowa Preliminary Motion 3 for judgment under 35 U.S.C. §135(b)) (Electronically filed, unsigned). October 15, 2004.	
*C152	Patent Interference No. 105,171. Iowa Reply 4 (in support of Iowa Preliminary Motion for judgment of no interference in fact) (Electronically filed, unsigned). October 15, 2004.	
*C153	Patent Interference No. 105,171. Iowa Reply 5 (in support of Iowa Preliminary Motion 5 for judgment that UC's claim 205 is not enabled) (Electronically filed, unsigned). October 15, 2004.	
*C154	Patent Interference No. 105,171. Iowa Reply 6 (in support of Iowa Preliminary Motion 6 for judgment based on lack of adequate written description) (Electronically filed, unsigned). October 15, 2004.	
*C155	Patent Interference No. 105,171. Iowa Reply 7 (in support of Iowa Preliminary Motion 7 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
*C156	Patent Interference No. 105,171. Iowa Reply 8 (in support of Iowa Preliminary Motion 8 to redefine the count) (Electronically filed, unsigned). October 15, 2004.	
*C157	Patent Interference No. 105,171. Iowa Reply 10 (in support of Iowa Preliminary Motion 10 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
*C158	Patent Interference No. 105,171. Iowa Reply 11 (in support of Iowa Miscellaneous Motion to suppress). (Electronically filed, unsigned). October 18, 2004.	
*C159	Patent Interference No. 105,171. Regents of the University of California Preliminary Statement. June 7, 2004.	
*C160	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 1 (to designate additional claims of Iowa patent as corresponding to the Count). June 7, 2004.	
*C161	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 2 (for judgment based on lack of written description support and introducing new matter). June 7, 2004.	
*C162	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 3 (for judgment based on anticipation). June 7, 2004.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/679,710	ATTY. DOCKET NO.: C1039.70074US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: October 3, 2003	CONFIRMATION NO.: 9983
				APPLICANT: Krieg et al.	
Sheet	16	of	17	GROUP ART UNIT: 1648	EXAMINER: Michelle S. Horning

*C163	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 4 (for judgment based on obviousness). June 7, 2004.	
*C164	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 5 (for judgment based on anticipation). June 7, 2004.	
*C165	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 6 (for judgment based on inequitable conduct). June 7, 2004.	
*C166	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 7 (for benefit of an earlier application under 37 CFR 1.633(j)). July 2, 2004.	
*C167	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 8 (to add additional claims under 37 CFR 1.633(c)(2) and (i)). July 2, 2004.	
*C168	Amended Claims for Application Number 09/265,191, filed March 10, 1999.	
*C169	Patent Interference No. 105,171. Iowa Opposition 1 (opposition to motion to designate additional claims as corresponding to the Count) (Electronically filed, unsigned). September 9, 2004.	
*C170	Patent Interference No. 105,171. Iowa Opposition 2 (opposition to motion for judgment based on lack of written description support and introducing new matter) (Electronically filed, unsigned). September 9, 2004.	
*C171	Patent Interference No. 105,171. Iowa Opposition 3 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
*C172	Patent Interference No. 105,171. Iowa Opposition 4 (opposition to motion for judgment based on obviousness) (Electronically filed, unsigned). September 9, 2004.	
*C174	Patent Interference No. 105,171. Iowa Opposition 5 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
*C174	Patent Interference No. 105,171. Iowa Opposition 6 (opposition to motion for judgment based on inequitable conduct) (Electronically filed, unsigned). September 9, 2004.	
*C176	Patent Interference No. 105,171. Iowa Opposition 7 (opposition to motion for benefit of an earlier application under 7 CFR 1.633(j)) (Electronically filed, unsigned). September 9, 2004.	
*C176	Patent Interference No. 105,171. Iowa Opposition 8 (opposition to motion to add additional claims under 37 CFR 1.633 (2) and (i)) (Electronically filed, unsigned). September 9, 2004.	
*C177	Patent Interference No. 105,171. Regents of the University of California Reply 1 (to Iowa's opposition to UC's motion to designate Iowa claims as corresponding to the Count). October 15, 2004.	
*C178	Patent Interference No. 105,171. Regents of the University of California Reply 2 (to Iowa's opposition to UC Preliminary Motion 2 for Judgment). October 15, 2004.	
*C179	Patent Interference No. 105,171. Regents of the University of California Reply 3 (to Iowa's Opposition to UC Preliminary Motion 3 for Judgment). October 15, 2004.	
*C180	Patent Interference No. 105,171. Regents of the University of California Reply 4 (to Iowa's Opposition to UC Preliminary Motion 4 for Judgment). October 15, 2004.	
*C181	Patent Interference No. 105,171. Regents of the University of California Reply 5 (to Iowa's Opposition to UC Preliminary Motion 5 for Judgment). October 15, 2004.	
*C182	Patent Interference No. 105,171. Regents of the University of California Reply 6 (to Iowa's opposition to UC Preliminary Motion 6 for judgment). October 15, 2004.	
*C183	Patent Interference No. 105,171. Regents of the University of California Reply 7 (to Iowa's Opposition to UC Preliminary Motion 7 for Benefit). October 15, 2004.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/679,710	ATTY. DOCKET NO.: C1039.70074US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: October 3, 2003	CONFIRMATION NO.: 9983
				APPLICANT: Krieg et al.	
Sheet	17	of	17	GROUP ART UNIT: 1648	EXAMINER: Michelle S. Horning

	*C184	Patent Interference No. 105,171. Regents of the University of California Reply 8 (to Iowa's Opposition to UC Preliminary Motion 8 to add additional claims). October 15, 2004.	
	*C185	Patent Interference No. 105,171. Decision on Motion under 37 CFR §41.125. March 10, 2005.	
	*C186	Patent Interference No. 105,171. Judgment and Order. March 10, 2005.	
	*C187	Patent Interference No. 105,171. Regents of the University of California. Brief of Appellant. July 5, 2005.	
	*C188	Patent Interference No. 105,171. University of Iowa and Coley Pharmaceutical Group, Inc. Brief of Appellees. August 17, 2005.	
	*C189	Patent Interference No. 105,171. Regents of the University of California. Reply Brief of Appellant. September 6, 2005.	
	*C190	Patent Interference No. 105,171. Regents of the University of California. Decision of CAFC. July 17, 2006.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918, filed March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.